Decreasing efficacy of the standard seven-day triple therapy containing amoxycillin and clarithromycin in curing Helicobacter pylori infection in clinical setting in Italy: A 10-year follow-up study

Panminerva Medica

Volumn 56, Issue 1, 2014, Pages 57-61

  Tursi, A ^a   Elisei, W ^b   Giorgetti, G ^c   Picchio, M ^d   Brandimarte, G ^e  

^a ASL BAT   (Italy)

^b ASL Roma H   (Italy)

^c S EUGENIO HOSPITAL   (Italy)

^d Hospital P Colombo   (Italy)

^e Cristo Re Hospital   (Italy)

Author keywords

Amoxycillin; Clarithromycin; Helicobacter pylori

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; CLARITHROMYCIN; PROTON PUMP INHIBITOR;

ADULT; AGED; BREATH ANALYSIS; DRUG ADMINISTRATION; ENDOSCOPY; FEMALE; FOLLOW UP; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMAN; ITALY; MALE; MIDDLE AGED; PEPTIC ULCER; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME;

ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; BREATH TESTS; CLARITHROMYCIN; DRUG ADMINISTRATION SCHEDULE; ENDOSCOPY; FEMALE; FOLLOW-UP STUDIES; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; ITALY; MALE; MIDDLE AGED; PEPTIC ULCER; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84899740318     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Cammarota G, Tursi A, Montalto M, Papa A, Cuoco L, Veneto GM et al. Clinical assessment of the relationship of H.pylori to gastroduodenal pathologies: A prospective analysis of 228 consecutive patients. Panminerva Med 1995;37:178-81
2. Cammarota G, Tursi A, Montalto M, Papa A, Branca G, Vecchio FM et al. Prevention and treatment of low-grade B-cell primary gastric lymphoma by anti-H. pylori therapy. J Clin Gastroenterol 1995;21:118-22.
3. Compare D, Rocco A, Nardone G. Risk factors in gastric cancer. Eur Rev Med Pharmacol Sci 2010;14:302-8.
4. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-81. (Pubitemid 46854190)
5. Mégraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53:1374-84. (Pubitemid 39120130)
6. Maconi G, Tosetti C, Miroglio G, Parente F, Colombo E, Sainaghi M et al. Management of Helicobacter pylon-related gastrointestinal diseases by general practitioners in Italy. Aliment Pharmacol Ther 1999;13:1499-504. (Pubitemid 29516263)
7. Della Monica P, Lavagna A, Masoero G, Lombardo L, Crocellá L, Pera A. Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy. Aliment Pharmacol Ther 2002;16:1269-75.
8. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F et al; European helicobacter study group. Management of helicobacter pylori infection-the maastricht IV/ florence consensus report. Gut 2012;61:646-64.
9. The European Helicobacter pylori Study Group. Current european concepts in the management of helicobacter pylori infection. Gut 1997;41(Suppl.2):8-13.
10. Laine L, Estrada R, Trujillo M, Knigge K, Fennerty MB. Effect of proton-pump inhibitor therapy as diagnostic testing for Helicobacter pylori. Ann Intern Med 1998;129:547-50. (Pubitemid 28460295)
11. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group. Gut 1997;41:8-13.
12. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59:1143-53.
13. Tursi A, Cammarota G, Montalto M, Papa A, Veneto G, Cuoco L et al Low-dose omeprazole plus clarithromycin and either tinidazole or amoxycillin for Helicobacter pylori infection. Aliment Pharmacol Ther 1996;10: 285-8 (Pubitemid 26173875)
14. Vaira D, Zullo A, Vakil N, Gatta L, Ricci C, Perna et al Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: A randomized trial. Ann Intern Med 2007;146:556-63.
15. Zagari RM, Bianchi-Porro G, Fiocca R, Gasbarrini G, Roda E, Bazzoli F. Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. Gut 2007;56:475-9. (Pubitemid 46580501)
16. Ang TL, Wang L, Ang D, Chiam P, Fock KM, Teo EK. Is there still a role for empiric first line triple therapy using proton pump inhibitor, amoxicillin and clarithromycin for Helicobacter pylori infection in Singapore? Results of a time trend analysis. J Dig Dis 2012 [Epub ahead of print].
17. Yoon JH, Baik GH, Sohn KM, Kim DY, Kim YS, Suk KT et al Trends in the eradication rates of Helicobacter pylori infection for eleven years. World J Gastroenterol 2012;18:6628-34.
18. Gisbert JP, Calvet X. Review article: The effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther 2011;34:1255-68.
19. De Francesco V, Margiotta M, Zullo A, Hassan C, Giorgio F, Burattini O et al Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy. J Antimicrob Chemother 2007;59:783-5. (Pubitemid 47073419)
20. De Francesco V, Giorgio F, Ierardi E, Zotti M, Neri M, Milano A et al Primary clarithromycin resistance in Helicobacter pylori: The Multicentric Italian Clarithromycin Resistance Observational (MICRO) study. J Gastrointestin Liver Dis 2011;20:235-9.
21. Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM et al Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013;62:34-42.
22. O'Connor A, Gisbert JP, McNamara D, O'Morain C. Treatment of Helicobacter pylori infection 2010. Helicobacter 2010;(Suppl 1):46-52.
23. Cuadrado-Lavín A, Salcines-Caviedes JR, Carrascosa MF, Dierssen-Sotos T, Cobo M, Campos MR et al Levofloxacin versus clarithromycin in a 10 day triple therapy regimen for first-line Helicobacter pylori eradication: A single-blind randomized clinical trial. J Antimicrob Chemother 2012;67:2254-9.
24. Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F, Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007;147:553-62. (Pubitemid 351664506)
25. De Francesco V, Margiotta M, Zullo A, Hassan C, Troiani L, Burattini O et al Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Intern Med 2006;144:94-100. (Pubitemid 46768227)
26. Liou JM, Chen CC, Chen MJ, Chang CY, Fang YJ, Lee JY et al; for the taiwan helicobacter consortium. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: A multicentre, open-label, randomised trial. Lancet 2012 [Epub ahead of print].
27. De Francesco V, Zullo A, Margiotta M, Marangi S, Burattini O, Beŕloco P el al Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure. Aliment Pharmacol Ther 2004:19:407-14. (Pubitemid 38297109)